Share This Page
Atorvastatin calcium; ezetimibe - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for atorvastatin calcium; ezetimibe and what is the scope of patent protection?
Atorvastatin calcium; ezetimibe
is the generic ingredient in two branded drugs marketed by Organon and Pharmobedient, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.Summary for atorvastatin calcium; ezetimibe
| US Patents: | 0 |
| Tradenames: | 2 |
| Applicants: | 2 |
| NDAs: | 2 |
| Clinical Trials: | 4 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for atorvastatin calcium; ezetimibe |
| DailyMed Link: | atorvastatin calcium; ezetimibe at DailyMed |
Recent Clinical Trials for atorvastatin calcium; ezetimibe
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Linyi People's Hospital | PHASE2 |
| Chinese University of Hong Kong | PHASE2 |
| Chong Kun Dang Pharmaceutical | Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for atorvastatin calcium; ezetimibe
US Patents and Regulatory Information for atorvastatin calcium; ezetimibe
Atorvastatin Calcium and Ezetimibe Market Dynamics, Patent Expiry, and Financial Trajectory
Atorvastatin calcium is a mature, highly commoditized statin with global generic competition and limited branded revenue. Ezetimibe retains greater commercial value because it is used as an add-on or alternative to statin therapy, but its core U.S. exclusivity has also expired. The atorvastatin-ezetimibe combination remains commercially relevant through generic fixed-dose products and European brands such as Atozet, although price pressure is increasing.
What are atorvastatin calcium and ezetimibe used for?
Atorvastatin calcium is an HMG-CoA reductase inhibitor used to reduce low-density lipoprotein cholesterol, total cholesterol, triglycerides, and cardiovascular risk. Ezetimibe inhibits intestinal cholesterol absorption through the NPC1L1 pathway and is used alone or with a statin.
The combination addresses patients who do not reach LDL-C targets with statin therapy alone or who require additional LDL reduction without substantially increasing statin exposure.
| Product | Active ingredient | Drug class | Primary use | Current market status |
|---|---|---|---|---|
| Lipitor and generic atorvastatin | Atorvastatin calcium | Statin | Hypercholesterolemia and cardiovascular risk reduction | Fully genericized |
| Zetia and generic ezetimibe | Ezetimibe | Cholesterol absorption inhibitor | Hypercholesterolemia and cardiovascular risk reduction | Generic competition |
| Vytorin | Ezetimibe/simvastatin | Fixed-dose combination | Hypercholesterolemia | Mature, largely generic |
| Liptruzet | Ezetimibe/atorvastatin | Fixed-dose combination | Hypercholesterolemia | U.S. brand discontinued |
| Atozet and generic equivalents | Ezetimibe/atorvastatin | Fixed-dose combination | Hypercholesterolemia | Active in several non-U.S. markets |
The FDA label for ezetimibe supports use with statins, fenofibrate, or alone in selected patients. The atorvastatin label supports a broad range of doses, generally from 10 mg to 80 mg daily.[1,2]
How large is the atorvastatin and ezetimibe market?
Atorvastatin is one of the largest generic pharmaceutical markets by prescription volume. Its economic value comes from scale rather than exclusivity. Ezetimibe has a smaller prescription base but higher revenue per prescription in branded and combination markets.
Atorvastatin market dynamics
Lipitor, marketed by Pfizer, was the world’s leading pharmaceutical product before patent expiry. Global annual sales exceeded $10 billion at peak and reached approximately $13 billion in 2010.[3] U.S. generic entry began after expiration of the principal atorvastatin patent estate in 2011.
The post-expiry market developed rapidly:
- Multiple manufacturers entered the U.S. market.
- Wholesale prices fell sharply.
- Retail and mail-order channels shifted toward low-cost generic supply.
- Pharmacy benefit managers treated atorvastatin as a preferred or lowest-cost statin.
- Brand Lipitor became a limited niche product.
Current value is distributed among manufacturers such as Viatris, Teva, Sandoz, Dr. Reddy's Laboratories, Sun Pharma, Zydus, Torrent, and numerous regional suppliers. No single company controls the global atorvastatin market.
Ezetimibe market dynamics
Ezetimibe initially had a more concentrated commercial market. Merck marketed Zetia and Vytorin, while Schering-Plough and Merck controlled the original U.S. commercialization structure before the companies merged.
Zetia generated approximately $2.4 billion in global sales in 2016 before broader generic erosion. Organon inherited the product portfolio following Merck's 2021 spinoff of its women's health, established brands, and biosimilars businesses. Organon's cardiovascular portfolio, including Zetia and related products, continues to produce material revenue, although generic competition limits pricing power.[4,5]
Ezetimibe remains commercially durable because:
- It is widely used as an add-on to high-intensity statins.
- It has a low-cost generic price point.
- It is incorporated into treatment pathways for patients who do not reach LDL targets on statins.
- It is used when higher statin doses are poorly tolerated.
- It is included in fixed-dose combinations with atorvastatin, rosuvastatin, and simvastatin.
What patents protect atorvastatin calcium and ezetimibe?
The core composition-of-matter patents for both molecules have expired. Commercial protection now depends on secondary patents, regulatory exclusivities in limited markets, trademarks, manufacturing scale, and distribution contracts.
| Drug | Representative originator | Core patent position | U.S. generic status | Current protection |
|---|---|---|---|---|
| Atorvastatin calcium | Pfizer | U.S. Patent No. 4,681,893 and related atorvastatin patents | Generic entry began in 2011 | No meaningful core-molecule exclusivity |
| Ezetimibe | Merck/Schering-Plough | U.S. Patent No. 5,767,115 and related patents | Generic entry followed expiry of core protection and litigation settlements | Limited secondary protection; no broad U.S. market exclusivity |
| Ezetimibe/atorvastatin | Merck and commercial partners | Combination and formulation patents in multiple jurisdictions | Generic and regional products available | Product-specific formulation and jurisdictional claims |
Atorvastatin's principal U.S. patent protection expired in 2011, with pediatric exclusivity extending the effective period for some products. Ezetimibe's key U.S. exclusivity period ended later, with generic competition becoming commercially significant from 2017 onward.[6,7]
Patent protection varies by country. European, Canadian, Japanese, and emerging-market expiration dates can differ because of patent filing dates, supplementary protection certificates, pediatric extensions, national opposition proceedings, and local settlements.
When did atorvastatin and ezetimibe lose exclusivity?
Atorvastatin exclusivity timeline
| Date | Event |
|---|---|
| 1987 | Lipitor received U.S. FDA approval |
| 1990s-2000s | Pfizer expanded global commercialization |
| 2011 | Core U.S. patent protection expired; generic entry began |
| 2012 onward | Generic atorvastatin became the dominant U.S. supply source |
| 2015 onward | Brand Lipitor became a small residual market |
Generic atorvastatin entered the U.S. market through multiple abbreviated new drug applications. The first-wave entrants captured substantial share because atorvastatin was already a high-volume product with established clinical demand.
Ezetimibe exclusivity timeline
| Date | Event |
|---|---|
| 2002 | Zetia received U.S. approval |
| 2004 | Vytorin, the ezetimibe/simvastatin combination, received U.S. approval |
| 2016 | Core U.S. patent term approached expiration |
| 2017-2018 | Generic ezetimibe and combination competition expanded |
| 2020 onward | Branded revenue continued but with sustained generic erosion |
Ezetimibe retained value after patent expiry because it had strong guideline familiarity, high physician awareness, and a large installed base of statin-treated patients. The product therefore experienced a slower commercial decline than many small-molecule drugs with similar patent histories.
What is the FDA and Orange Book status of these products?
Atorvastatin, ezetimibe, and several combinations are approved small-molecule products listed in FDA databases. Their market access is governed primarily through abbreviated new drug applications rather than biologics licensing applications.
The FDA Orange Book records patents and regulatory exclusivity relevant to listed products. For mature generic products, Orange Book listings are less commercially decisive than they are for newly launched medicines because:
- Core composition patents have expired.
- Multiple ANDA holders are approved.
- Most remaining claims relate to formulations, combinations, or methods of use.
- Generic manufacturers can often design around secondary claims.
The FDA classifies atorvastatin and ezetimibe as small-molecule drugs. No biosimilar pathway applies. Competitors file ANDAs, demonstrate pharmaceutical equivalence and bioequivalence, and rely on the reference product's safety and efficacy findings.
Which companies challenged the patents?
Ezetimibe generated more meaningful Paragraph IV activity than atorvastatin because the reference product reached the market later and retained higher branded value at the time of generic challenge.
Generic applicants and potential challengers included major manufacturers such as Teva, Glenmark, Mylan, Dr. Reddy's Laboratories, and other ANDA sponsors. Challenges generally focused on patent validity, enforceability, and non-infringement.
Atorvastatin also produced significant patent litigation before generic launch. Pfizer litigated with multiple generic manufacturers over atorvastatin calcium and related formulations. The main commercial outcome was delayed generic entry followed by rapid erosion once the relevant barriers expired.
Paragraph IV litigation matters less today for the base molecules. The relevant risk has shifted toward:
- Fixed-dose combination claims.
- Polymorph and crystalline-form claims.
- Manufacturing-process claims.
- Pediatric and geriatric formulations.
- Modified-release or abuse-deterrent delivery claims, where applicable.
- Jurisdiction-specific patents outside the United States.
What formulations are protected by atorvastatin and ezetimibe patents?
The principal marketed forms are conventional immediate-release oral tablets. Formulation differentiation is limited, which reduces the scope for premium pricing.
Atorvastatin formulations
Commercial products include:
- 10 mg, 20 mg, 40 mg, and 80 mg tablets.
- Calcium salt formulations.
- Film-coated immediate-release tablets.
- Fixed-dose combinations with amlodipine, ezetimibe, and other cardiovascular agents.
Secondary intellectual property may cover salt form, particle characteristics, tablet composition, stability, and manufacturing processes. These claims generally do not prevent broad generic substitution when the generic product uses a non-infringing process or formulation.
Ezetimibe formulations
Commercial products include:
- 10 mg immediate-release tablets.
- Ezetimibe/simvastatin tablets.
- Ezetimibe/atorvastatin tablets.
- Ezetimibe/rosuvastatin combinations.
- Ezetimibe with antihypertensive combinations in selected markets.
The most defensible post-expiry opportunities are fixed-dose combinations and region-specific formulations. These products may secure separate approvals and regulatory listings even when the individual ingredients are fully genericized.
How strong is the patent estate for atorvastatin and ezetimibe?
The base-molecule patent estates are weak from a current commercial-exclusivity perspective.
| Factor | Atorvastatin | Ezetimibe |
|---|---|---|
| Core composition patent strength | Very low after expiry | Very low after expiry |
| Number of generic suppliers | High | High and increasing |
| Secondary formulation value | Low to moderate | Moderate |
| Combination-product value | Moderate | Moderate to high |
| Manufacturing barriers | Low to moderate | Moderate |
| Litigation leverage | Low | Low to moderate |
| Ability to sustain premium pricing | Minimal | Limited |
Ezetimibe has the stronger residual commercial position because it remains differentiated pharmacologically from statins and is embedded in combination therapy. Atorvastatin is more exposed to substitution by rosuvastatin, simvastatin, pravastatin, and other generic statins.
Neither drug has a patent estate comparable to a protected specialty medicine or biologic. The main barriers are operational rather than legal: active pharmaceutical ingredient quality, regulatory compliance, supply continuity, and tender access.
How does atorvastatin compare with ezetimibe financially?
| Metric | Atorvastatin calcium | Ezetimibe |
|---|---|---|
| Peak branded product | Lipitor | Zetia/Vytorin |
| Peak annual sales | About $13 billion globally | More than $2 billion for Zetia before full generic erosion |
| Patent expiry impact | Immediate and severe | Significant but more gradual |
| Current commercial model | High-volume generic | Generic base plus residual branded and combination revenue |
| Pricing power | Very low | Low to moderate in selected branded markets |
| Main competitors | Rosuvastatin, simvastatin, pravastatin, generics | Statins, PCSK9 inhibitors, bempedoic acid, inclisiran |
| Growth driver | Volume and procurement efficiency | Combination use and LDL target intensification |
| Main risk | Price compression | Generic substitution and therapeutic competition |
Atorvastatin's revenue trajectory is volume-led. Manufacturers can remain profitable at low prices because of large prescription volumes, established manufacturing processes, and predictable demand.
Ezetimibe retains better revenue quality in markets where branded prescriptions remain common. Organon's financial exposure is concentrated in mature brands and is vulnerable to continued price and volume erosion. Generic manufacturers can still generate attractive returns if they maintain supply reliability and secure preferred formulary positions.
What competitive drugs affect ezetimibe revenue?
Ezetimibe competes with both low-cost statins and newer LDL-lowering drugs.
Direct and adjacent competitors
- Rosuvastatin: high-intensity generic statin and the strongest direct alternative.
- Simvastatin and pravastatin: lower-cost generic statins.
- Bempedoic acid: oral non-statin option, particularly relevant for statin-intolerant patients.
- PCSK9 monoclonal antibodies: alirocumab and evolocumab, used mainly in high-risk patients.
- Inclisiran: long-acting PCSK9-directed therapy.
- Bile acid sequestrants and fibrates: narrower roles.
Ezetimibe generally occupies the low-cost non-statin step before expensive injectable therapies. That positioning supports prescription volume but limits pricing because payers often require generic ezetimibe before covering PCSK9 therapies.
What generic launch scenarios exist for atorvastatin-ezetimibe?
The combination market has three main launch scenarios.
Scenario 1: Standard generic substitution
Manufacturers launch bioequivalent tablets in commonly used strengths, including 10/10 mg, 10/20 mg, 10/40 mg, and 10/80 mg. Payers substitute these products rapidly, producing price declines similar to other cardiovascular generics.
Scenario 2: Regional fixed-dose expansion
Manufacturers target Europe, Latin America, Asia, and selected Middle Eastern markets where combination products have strong physician acceptance. Local brands and tender contracts may support higher margins than the U.S. market.
Scenario 3: Portfolio bundling
Large generic companies bundle atorvastatin-ezetimibe with rosuvastatin, antihypertensives, antiplatelets, and diabetes products. The value lies in procurement and sales coverage rather than patent exclusivity.
The largest risk to a new entrant is not patent infringement. It is obtaining competitive cost of goods, regulatory approvals across jurisdictions, and reliable supply at a price accepted by national health systems and pharmacy benefit managers.
What litigation and settlement issues affect these products?
The primary historical litigation involved:
- Pfizer's enforcement of atorvastatin patents against ANDA applicants.
- Merck and Schering-Plough enforcement of ezetimibe and ezetimibe-combination patents.
- Paragraph IV challenges involving validity, infringement, and patent-term interpretation.
- Settlements that controlled the timing of generic launch in specific jurisdictions.
Current litigation risk is lower for the base products because generic supply is established. New disputes are more likely to involve:
- Combination tablet patents.
- Brand-versus-generic substitution practices.
- Product labeling and method-of-use claims.
- Manufacturing processes.
- Regulatory exclusivity or data-protection rights outside the United States.
What licensing deals influence the market?
The most important commercial transactions were originator and portfolio transfers rather than new discovery licenses.
- Merck and Schering-Plough combined their operations, consolidating Zetia and Vytorin commercialization.
- Organon acquired the established-products portfolio when it separated from Merck in 2021.
- Generic companies expanded through supply agreements, regional licenses, and contract manufacturing arrangements.
Atorvastatin's commercial rights are broadly dispersed after Lipitor's patent expiry. Ezetimibe remains more concentrated in certain branded markets because Organon continues to commercialize Zetia and related products.
What is the revenue outlook for atorvastatin and ezetimibe?
Atorvastatin revenue should remain stable in aggregate but continue shifting from branded sales to low-margin generic volume. Growth is likely to come from population aging, cardiovascular risk screening, and expanded treatment guidelines rather than pricing.
Ezetimibe should retain a larger value pool than atorvastatin on a per-prescription basis. Its trajectory depends on:
- Continued statin intensification.
- Use in statin-intolerant patients.
- Adoption of combination tablets.
- Generic penetration.
- Competition from bempedoic acid and injectable LDL-lowering medicines.
- Reimbursement rules governing step therapy.
The financial profile is therefore defensive rather than high-growth. Neither molecule offers a credible near-term path to originator-like monopoly economics.
Key Takeaways
- Atorvastatin calcium is a fully genericized, high-volume statin market.
- Lipitor's core U.S. patent protection expired in 2011.
- Ezetimibe lost core U.S. exclusivity later, with generic competition expanding from 2017 onward.
- Ezetimibe retains greater commercial value because it is used as an add-on and in fixed-dose combinations.
- Neither product has meaningful biosimilar risk because both are small molecules subject to ANDA competition.
- Combination products, regional brands, manufacturing efficiency, and supply reliability are the main remaining commercial opportunities.
- Organon retains branded exposure through Zetia and related products, but generic erosion limits pricing power.
- Atorvastatin revenue is volume-driven; ezetimibe revenue has a stronger combination and branded-market component.
- Current patent risk is concentrated in formulations, combinations, manufacturing processes, and jurisdiction-specific claims.
- The long-term market outlook is stable in volume and declining in unit price.
FAQs
Does atorvastatin calcium still have patent protection?
The core U.S. atorvastatin patents expired in 2011, and multiple generic manufacturers supply the market. Remaining patents, where applicable, generally concern specific formulations, combinations, or manufacturing methods rather than the basic molecule.
Is ezetimibe still protected by the Orange Book?
Ezetimibe products may retain listed secondary patents, but the core U.S. exclusivity period has ended and generic ezetimibe is widely available. Orange Book listings should be reviewed product by product because patent coverage differs among Zetia, combination products, and authorized generics.
Is atorvastatin-ezetimibe a biosimilar product?
No. Atorvastatin-ezetimibe is a small-molecule fixed-dose combination. Competitors seek approval through ANDAs or equivalent national generic pathways, not through the biosimilar framework.
Which drug has stronger commercial prospects, atorvastatin or ezetimibe?
Ezetimibe has stronger residual commercial prospects because it has a differentiated mechanism and is used with statins. Atorvastatin has greater prescription volume but substantially lower pricing power.
Can a generic company obtain premium pricing for atorvastatin-ezetimibe?
Premium pricing is difficult in the United States because of generic substitution and payer control. Better economics may be available through differentiated strengths, regional approvals, supply contracts, and markets where fixed-dose combination use is established.
References
- U.S. Food and Drug Administration. (2024). Lipitor (atorvastatin calcium) prescribing information. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (2024). Zetia (ezetimibe) prescribing information. https://www.accessdata.fda.gov
- Pfizer Inc. (2011). Annual report 2010. https://www.pfizer.com/investors/financial-reports
- Merck & Co., Inc. (2017). Annual report 2016. https://www.merck.com/investor-relations/financial-information/
- Organon & Co. (2024). Annual report 2023. https://www.organon.com/investors/financial-information/
- U.S. Patent and Trademark Office. (1987). U.S. Patent No. 4,681,893: Trans-6-[2-(3- or 4-substituted-1H-indol-2-yl)ethyl]-2,2-dimethyl-1,3-dioxane-4-pentanoic acid. https://patents.google.com
- U.S. Patent and Trademark Office. (1998). U.S. Patent No. 5,767,115: Azetidinone compounds for the treatment of hypercholesterolemia. https://patents.google.com
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
More… ↓
